Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two-Drug attack on tough lymphoma shows promise in early trial

NCT ID NCT03278782

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether combining two drugs—pembrolizumab (Keytruda), which helps the immune system fight cancer, and romidepsin (Istodax), which blocks cancer cell growth—can safely treat peripheral T-cell lymphoma that has returned or not responded to prior therapy. The trial involves 39 participants and is in early phases (I/II) to check side effects and effectiveness. The goal is to see if the combo works better than either drug alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

pembrolizumab (Keytruda) and romidepsin (Istodax)

What this could lead to

If successful, this combination could offer a new treatment option for patients with peripheral T-cell lymphoma that has come back or stopped responding to other therapies.

What could go wrong

This is an early-phase trial with only 39 participants, so results may not apply to all patients. The combination may cause significant side effects, and it is not yet known if it works better than existing treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MYCOSIS FUNGOIDES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma mycosis fungoides peripheral T-cell lymphoma, not otherwise specified primary cutaneous T-cell non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT ANAPLASTIC LARGE CELL LYMPHOMA RECURRENT ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA RECURRENT MATURE T- AND NK-CELL NON-HODGKIN LYMPHOMA RECURRENT MYCOSIS FUNGOIDES RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA REFRACTORY MYCOSIS FUNGOIDES REFRACTORY PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States